Lupin gets USFDA nod for generic oral contraceptive tablets
Advertisement
New Delhi, Nov 24 : Lupin today said it has received US health regulator's final approval to market Blisovi oral contraceptive tablets in different strengths in the American market.
"The company has received final approvals from the United States Food and Drug Administration (USFDA) to market generic versions of Warner Chilcott's Loestrin Fe 1/20 tablets and Loestrin Fe 1.5/30 tablets", Lupin said in a statement.
"The company has received final approvals from the United States Food and Drug Administration (USFDA) to market generic versions of Warner Chilcott's Loestrin Fe 1/20 tablets and Loestrin Fe 1.5/30 tablets", Lupin said in a statement.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.